Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids

European Respiratory Journal

Volumn 19, Issue 1, 2002, Pages 182-191

  Barnes, P J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Asthma; Budesonide; Fluticasone propionate; Formoterol; Salmeterol

Indexed keywords

AUTACOID; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; GLUCOCORTICOID RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; SALMETEROL; THEOPHYLLINE;

ASTHMA; BRONCHODILATING ACTIVITY; CELL NUCLEUS; CELLULAR DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INHALER; INHIBITION KINETICS; LONG TERM CARE; MAST CELL; MEDIATOR RELEASE; MOLECULAR MECHANICS; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SENSORY NERVE CONDUCTION; SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MAST CELLS; NEURONS, AFFERENT; RECEPTORS, ADRENERGIC, BETA-2;

EID: 0036153433     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00283202     Document Type: Review

References (108)

1. Global strategy for asthma management and prevention
2. The expanding role of long-acting beta-agonists
3. Advair: Combination treatment with fluticasone propionate/salmeterol in the treatment of asthma
4. Inhaled salmeterol/fluticasone propionate combination: A review of its use in persistent asthma
5. Inhaled budesonide/formoterol combination
6. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
7. 2-agonist salmeterol xinafoate: Effects on airway inflammation in asthma
8. 2-agonists on airway inflammation in asthmatic patients
9. Comparison of addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids
10. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)
11. Effect of inhaled formoterol and budesonide on exacerbations of asthma
12. Exacerbations of asthma. A descriptive study of 425 severe exacerbations
13. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma
14. Low dose inhaled budesonide and formoterol in mild persistent asthma
15. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma
16. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma
17. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice
18. Long acting beta-agonists versus theophylline for maintenance treatment of asthma
19. Montelukast added to inhaled beclomethasone in treatment of asthma
20. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast
21. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy
22. Addition of an anti-leukotriene to therapy in chronic severe asthma in a clinic setting: A double-blind, randomised, placebo-controlled study
23. Efficacy and safety of inhaled corticosteroids: An update
24. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma
25. Inhaled beclomethasone at different doses for long-term asthma
26. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: Meta-analysis
27. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma
28. Effect of β-agonists on inflammatory cells
29. Influence of receptor reserve on β-adrenoceptor-mediated responses in human lung mast cells
30. Formoterol on airway smooth muscle and human lung mast cells: A comparison with salbutamol and salmeterol
31. Salmeterol inhibition of mediator release from human lung mast cells by β-adrenoceptor-dependent and independent mechanisms
32. Regulation of human mast cell and basophil function by cAMP
33. 2-agonists
34. 2-agonists
35. Adenosine induced broncho-constriction in asthma: Role of mast cell mediator release
36. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine
37. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma
38. Comparison of salmeterol and albuterol-induced bronchoconstriction against adenosine monophosphate and histamine in mild asthma
39. Effect of inhaled formoterol and budesonide on exacerbations of asthma
40. The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation
41. Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways
42. Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways
43. 2-adrenergic agonist formoterol
44. 2-adrenergic agonist formoterol
45. The effect of anti-asthma drugs on microvascular leak in guinea pig airways
46. Inhaled formoterol inhibits histamine-induced airflow obstruction and airway microvascular leakage
47. The anti-edema action of formoterol in rat trachea does not depend on capsaicin-sensitive sensory nerves
48. Anti-allergic actions of high topical doses of terbutaline in human nasal airways
49. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration
50. Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects
51. 2-Adrenoceptors inhibit NANC neural bronchoconstrictor responses in vitro
52. 2-adrenergic and anticholinergic drugs
53. Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids
54. 2-agonists
55. β-Adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids
56. 2-adrenergic receptor gene
57. 2-adrenergic receptor transcription in human lung
58. 2-adrenergic receptors in vivo
59. 2-adrenergic receptor function in human nasal mucosa
60. Long term exposure to norepinephrine results in down-regulation and reduced mRNA expression of pulmonary β-adrenergic receptors in guinea pigs
61. 2-adrenoceptor messenger RNA with prolonged in vivo infusion of isoprenaline
62. Beta-adrenoceptor reserve in human lung: A comparison between airway smooth muscle and mast cells
63. 2-adrenoceptor-mediated responses in human lung mast cells
64. An inhaled glucocorticoid does not prevent tolerance to salmeterol in mild asthma
65. Inhaled corticosteroids do not prevent the development of subsensitivity to salbutamol after twice daily salmeterol
66. Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
67. Mechanisms of impaired β-adrenergic receptor relaxation by interleukin-1β in vivo in rat
68. 2-adrenoceptor desensitization in vivo
69. Reversal of IL-1β-induced up-regulation of G-protein-coupled receptor kinase activity by dexamethasone
70. 2 receptor expression and function in airway smooth muscle
71. 2-receptor expression in bovine tracheal smooth muscle
72. Delayed eosinophil apoptosis in asthma
73. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes
74. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects
75. β-Adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung
76. Albuterol does not antagonize the inhibitory effect of dexamethasone on monocyte cytokine release
77. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
78. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation
79. 2-agonists and corticosteroids on tumor necrosis factor-α-induced interleukin-8 release from cultured human airway smooth-muscle cells
80. 2-agonists and corticosteroids
81. Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression
82. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells
83. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1β-induced histone H4 acetylation on lysines 8 and 12
84. p65-activated histone acetyltransferase activity is repressed by glucocorticoids: Mifepristone fails to recruit HDAC2 to the p65/HAT complex
85. Beta-adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IκB/NF-κB pathway
86. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma
87. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma
88. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial
89. Onset of bronchodilation of budesonide/ formoterol vs. salmeterol/fluticasone in single inhalers
90. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone
91. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma
92. Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma
93. Is overall asthma control being achieved? A hypothesis-generating study
94. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma
95. 2-agonist over three months on airway wall vascular remodeling in asthma
96. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics
97. Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults
98. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions
99. A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide
100. Clinical management of asthma in 1999: The Asthma Insights and Reality in Europe (AIRE) study
101. New Drugs for Asthma and COPD
102. Therapeutic strategies for allergic diseases
103. New treatments for asthma
104. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response
105. Results of a phase I trial with SCH55700, a humanized anti-IL-5 antibody in severe persistent asthma
106. Anti-IgE therapy in asthma: Rationale and therapeutic potential
107. Treatment of allergic asthma with monoclonal anti-IgE antibody
108. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics